文献速递肝病

SerpinB3多态性变异体(SerpinB3-PD)与肝硬化失代偿更快发生相关

The polymorphic variant of SerpinB3 (SerpinB3-PD) is associated with faster cirrhosis decompensation.
PubMed 文献 · Aliment Pharmacol Ther · 2023-11-21

本研究在90例前瞻性随访的肝硬化患者中评估SerpinB3-PD多态性,发现携带SB3-PD者门静脉高压更严重、MELD评分更高,且SB3-PD是肝硬化并发症的独立预测因子;体外实验显示SB3-PD可上调TGF-β1并促进炎症反应。

要点

  • 携带SB3-PD的肝硬化患者门静脉高压更严重且MELD评分更高。
  • 多因素分析显示SB3-PD是肝硬化并发症的独立预测因子。
  • 体外实验中重组SB3-PD较SB3-WT更显著上调TGF-β1并促进炎症。

核心结论

  • 多态性变异体SB3-PD在体外能有效激活TGF-β1和炎症。
  • 携带SB3-PD的肝硬化患者可能更易发生严重肝病进展。
  • 需要进一步验证研究来支持该多态性的体内相关性。

研究设计与样本

  • 前瞻性随访90例在本转诊中心随访的肝硬化患者,评估SB3多态性。
  • 体外使用过表达SB3-WT或SB3-PD的HepG2和HuH-7细胞评估内源性效应。
  • 用外源性SB3-WT或SB3-PD蛋白处理LX2和THP-1细胞。

主要发现

  • 携带SB3-PD的患者较携带SB3-WT的患者门静脉高压更严重且MELD评分更高。
  • 多因素分析中SB3-PD是肝硬化并发症的独立预测因子。
  • 携带SB3-PD多态性的患者肝纤维化和炎症特征更严重。
  • 过表达SB3-PD的肝癌细胞TGF-β1表达高于对照。
  • 重组SB3-PD较SB3-WT蛋白更显著上调LX2细胞TGF-β1并诱导THP-1细胞更明显的炎症特征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步验证研究来支持该多态性的体内相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SerpinB3 is a cysteine protease inhibitor involved in liver disease progression due to its proinflammatory and profibrogenic properties. The polymorphic variant SerpinB3-PD (SB3-PD), presents a substitution in its reactive centre loop, determining the gain of function. AIMS: To disclose the clinical characteristics of a cohort of patients with cirrhosis in relation to the presence of SB3-PD and to assess the effect of this genetic variant on fibrogenic and inflammatory cytokines in vitro. METHODS: We assessed SB3 polymorphism in 90 patients with cirrhosis, prospectively followed up in our referral centre. We used HepG2 and HuH-7 cells transfected to overexpress either wild-type SB3 (SB3-WT) or SB3-PD to assess their endogenous effect, while LX2 and THP-1 cells were treated with exogenous SB3-WT or SB3-PD proteins. RESULTS: Patients carrying SB3-PD had more severe portal hypertension and higher MELD scores, than patients carrying SB3-WT. In multivariate analysis, SB3-PD was an independent predictor of cirrhosis complications. Patients with SB3-PD polymorphism presented with more severe liver fibrosis and inflammatory features. Hepatoma cells overexpressing SB3-PD showed higher TGF-β1 expression than controls. The addition of recombinant SB3-PD induced an up-regulation of TGF-β1 in LX2 cells and a more prominent inflammatory profile in THP-1 cells, compared to the effect of SB3-WT protein. CONCLUSIONS: The polymorphic variant SB3-PD is highly effective in determining activation of TGF-β1 and inflammation in vitro. Patients with cirrhosis who carry SB3-PD polymorphism may be more prone to develop severe liver disease progression. However, further validation studies are warranted to support the in vivo relevance of this polymorphism.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Martini A, Turato C, Cannito S, et al. The polymorphic variant of SerpinB3 (SerpinB3-PD) is associated with faster cirrhosis decompensation. Aliment Pharmacol Ther. 2023. PMID: 37990490. doi:10.1111/apt.17804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。